Search Results - "Singhrao, Ruby"

Evaluation of Navify Mutation Profiler Tertiary Analysis Software Assessing for Hematologic Malignancies †.

Authors: Singhrao, Ruby Clark, Michael J. Chugh, Shikha et al.

Source: Journal of Molecular Pathology. Jun2025, Vol. 6 Issue 2, p9-N.PAG. 13p.

Reproductive and Maternal Health in the Post-2015 Era: Cervical Cancer Must Be a Priority.

Authors: Singhrao, Ruby Huchko, Megan Yamey, Gavin

Source: PLoS Medicine. Aug2013, Vol. 10 Issue 8, p1-4. 4p. 1 Diagram.

The Value of Clinical Decision Support in Healthcare: A Focus on Screening and Early Detection.

Authors: Schäfer, Hendrik Lajmi, Nesrine Valente, Paolo et al.

Source: Diagnostics (2075-4418). Mar2025, Vol. 15 Issue 5, p648. 41p.

Focal treatment for high-grade cervical intraepithelial neoplasia: a pilot study.

Authors: Craig, Amaranta D. Khan, Michelle J. Singhrao, Ruby et al.

Source: Gynecologic Oncology. Oct2017, Vol. 147 Issue 1, p209-209. 1p.

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.

Authors: Rugo HS Campbell M Yau C et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Feb; Vol. 209 (3), pp. 487-492. Date of Electronic Publication: 2024 Dec 03.

Publication Type: Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.

Authors: Lang JE Forero-Torres A Yee D et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2022 Dec 01; Vol. 8 (1), pp. 128. Date of Electronic Publication: 2022 Dec 01.

Publication Type: Journal Article

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2⁺ breast cancer in the adaptively randomized I-SPY2 trial.

Authors: Clark AS Yau C Wolf DM et al.

Source: Nature communications [Nat Commun] 2021 Nov 05; Vol. 12 (1), pp. 6428. Date of Electronic Publication: 2021 Nov 05.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Adaptive Clinical Trial

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

Authors: Yee D Isaacs C Wolf DM et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2021 Oct 05; Vol. 7 (1), pp. 131. Date of Electronic Publication: 2021 Oct 05.

Publication Type: Journal Article

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Authors: Albain KS Yau C Petricoin EF et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 16; Vol. 30 (4), pp. 729-740.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Authors: Pusztai L Yau C Wolf DM et al.

Source: Cancer cell [Cancer Cell] 2021 Jul 12; Vol. 39 (7), pp. 989-998.e5. Date of Electronic Publication: 2021 Jun 17.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

Authors: Yee D DeMichele AM Yau C et al.

Corporate Authors: Yee D DeMichele AM Yau C et al.

Source: JAMA oncology [JAMA Oncol] 2020 Sep 01; Vol. 6 (9), pp. 1355-1362.

Publication Type: Journal Article; Randomized Controlled Trial; Adaptive Clinical Trial

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

Authors: Nanda R Liu MC Yau C et al.

Source: JAMA oncology [JAMA Oncol] 2020 May 01; Vol. 6 (5), pp. 676-684.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Adaptive Clinical Trial

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

Authors: Chien AJ Tripathy D Albain KS et al.

Corporate Authors: Chien AJ Tripathy D Albain KS et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Apr 01; Vol. 38 (10), pp. 1059-1069. Date of Electronic Publication: 2019 Feb 07.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Adaptive Clinical Trial

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE